{{Rsnum
|rsid=751402
|Gene=BIVM-ERCC5
|Chromosome=13
|position=102845848
|Orientation=minus
|GMAF=0.2906
|Gene_s=BIVM-ERCC5,ERCC5
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 63.4 | 32.1 | 4.5
| HCB | 40.7 | 45.2 | 14.1
| JPT | 38.9 | 46.9 | 14.2
| YRI | 42.2 | 49.7 | 8.2
| ASW | 49.1 | 42.1 | 8.8
| CHB | 40.7 | 45.2 | 14.1
| CHD | 35.8 | 53.2 | 11.0
| GIH | 44.6 | 49.5 | 5.9
| LWK | 44.0 | 48.6 | 7.3
| MEX | 40.4 | 43.9 | 15.8
| MKK | 53.9 | 41.4 | 4.6
| TSI | 56.9 | 39.2 | 3.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=24353624
|Title=XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer
|OA=1
}}

{{PMID Auto
|PMID=20233728
|Title=Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium.
|OA=1
}}

{{PMID Auto
|PMID=22981091
|Title=Association between polymorphisms of DNA repair gene ERCC5 and oral squamous cell carcinoma.
}}

{{PMID Auto
|PMID=22982416
|Title=Promoter polymorphisms in DNA repair gene ERCC5 and susceptibility to gastric cancer in Chinese.
}}

{{PMID Auto
|PMID=23211354
|Title=Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}